Investigational drug · Phase 2
B group Purinostat Mesylate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor.
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "B group Purinostat Mesylate"
First trial start
2024
May 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B group Purinostat Mesylate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "B group Purinostat Mesylate" as an intervention, largest first.
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07011056 · 390 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 30, 2029
Drug: Purinostat Mesylate for Injection; Selinexor Tablets · For: Recurrent and Refractory Diffuse Large B-cell Lymphoma
Sites: Chengdu, China
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06484829 · 144 participants (planned) · Start Mar 25, 2024 · Primary completion Feb 1, 2026
Drug: Purinostat Mesylate 4 mg/m2; Purinostat Mesylate 6 mg/m2 and 1 more · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Chengdu, China
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid TumorsRecruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT06431243 · 132 participants (planned) · Start May 8, 2024 · Primary completion May 1, 2026
Drug: A0/B0 group Purinostat Mesylate 11.2mg/m2; A0/B0 group Purinostat Mesylate 15mg/m2 and 8 more · For: Advanced Solid Tumor
Sites: Guanzhou, China; Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.